Video Experimental Relacionado
Updated: Sep 10, 2025
11:06
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.2K
Los antinutrientes botánicos como moduladores naturales de la hiperglucemia y la hiperlipidemia postprandial: una
Anuj Kumar Borah1,2, Sagnik Nag3, Megha Chetri2
1Department of Biotechnology, Royal School of Bio-Sciences, The Assam Royal Global University, Guwahati, Assam, India.
Phytotherapy research : PTR
|August 25, 2025
Resumen
Los antinutrientes botánicos pueden ayudar a controlar los niveles de azúcar y lípidos en la sangre después de las comidas. Compuestos como el ácido betulínico y la berberina son prometedores en modelos animales para combatir la hiperglucemia y la hiperlipidemia.
Área de la Ciencia:
- Farmacología y Fitoquímica
- Trastornos Metabólicos Investigación
- Ciencias de la nutrición
Sus antecedentes:
- La hiperglucemia postprandial y la hiperlipidemia plantean desafíos fisiológicos significativos.
- Los antinutrientes, en particular las fuentes botánicas, se exploran por su potencial para modular la absorción de nutrientes.
- El control de estas elevaciones postprandial es clave para mantener la homeostasis sistémica.
Objetivo del estudio:
- Investigar los antinutrientes botánicos para modular la digestión intestinal de los carbohidratos y los lípidos.
- Identificar compuestos derivados de plantas que pueden minimizar las elevaciones de monosacáridos y lípidos en la sangre postprandial.
- Revisar la evidencia de los antinutrientes naturales en el tratamiento de los trastornos metabólicos.
Principales métodos:
- Búsqueda de literatura a través de Google Scholar, PubMed y Scopus utilizando palabras clave específicas.
- Incluir los estudios in vitro (enzimáticos, basados en células) y in vivo (modelos animales).
- Exclusión de los compuestos microbianos y en los estudios únicamente en silicio.
Principales resultados:
- Varios antinutrientes botánicos demuestran evidencia para modular la absorción de carbohidratos y lípidos.
- El ácido betulínico, el vaticanol A, el vaticanol E y la berberina abordaron eficazmente la hiperglucemia y la hiperlipidemia en modelos animales.
- Se encontró que estos compuestos se dirigen a la ciclooxigenasa-2 (COX2), implicada en trastornos metabólicos.
Conclusiones:
- Los compuestos botánicos muestran potencial como solución única para la hiperglucemia y la hiperlipidemia, a través de monoterapia o terapia combinada.
- Se necesita más investigación para validar la eficacia in vivo, optimizar la dosis y evaluar la seguridad y eficacia clínicas.
- Estos antinutrientes naturales representan una vía prometedora para manejar la desregulación metabólica.
Videos de Conceptos Relacionados
01:19Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
256
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
256
01:24Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
01:06Oral Hypoglycemic Agents: Glinides
257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
01:23Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
01:16Hormones Regulating Blood Glucose
4.0K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
4.0K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
291
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
291